TapewireFind a company

person · Reporting owner

Smith Stan

Disclosed activity across 1 company

Tapewire entity
32976
SEC CIK
0001913199

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MAIA Biotechnology, Inc.MAIA · Entity 6919DirectorSeptember 30, 2026October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MAIA Biotechnology, Inc.

Report date September 30, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-09-30IndirectSee footnote38,871 Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-09-30 · Grant · Acquired 38,871 · Balance 38,871

F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 21, 2023 Filed Mar 22, 2023 10:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 2,736 $3.17 $8,673.12
Disclosure

SEC source: 0001127602-23-010968 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 539,070

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.57 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 20, 2023 Filed Mar 22, 2023 10:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 3,006 $3.28 $9,859.68
Disclosure

SEC source: 0001127602-23-010968 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 536,334

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.18 to $3.345 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 09, 2023 Filed Mar 13, 2023 10:25 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 3,582 $4.03 $14,435.46
Disclosure

SEC source: 0001127602-23-009811 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 533,328

F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.165, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
March 08, 2023 Filed Mar 9, 2023 11:30 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 3,076 $4.20 $12,919.20
Disclosure

SEC source: 0001127602-23-009534 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 529,746

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.06 to $4.25 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 11:30 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 1,961 $4.23 $8,295.03
Disclosure

SEC source: 0001127602-23-009534 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 526,670

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 06, 2023 Filed Mar 7, 2023 11:33 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 4,594 $4.39 $20,167.66
Disclosure

SEC source: 0001127602-23-009205 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 524,709

F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.50 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 11:33 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 2,509 $4.43 $11,114.87
Disclosure

SEC source: 0001127602-23-009205 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 520,115

F1 · shares: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · shares: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.39 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
March 02, 2023 Filed Mar 3, 2023 11:10 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 23 $4.41 $101.43
Disclosure

SEC source: 0001127602-23-008532 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 517,606

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 11:10 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 198 $4.48 $887.04
Disclosure

SEC source: 0001127602-23-008532 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 517,583

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.43 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 28, 2023 Filed Mar 1, 2023 11:38 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 1,619 $4.48 $7,253.12
Disclosure

SEC source: 0001127602-23-007701 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 517,385

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.43 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 27, 2023 Filed Mar 1, 2023 11:38 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 219 $4.47 $978.93
Disclosure

SEC source: 0001127602-23-007701 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 515,766

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 22, 2023 Filed Feb 23, 2023 11:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 1,073 $4.48 $4,807.04
Disclosure

SEC source: 0001127602-23-006606 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 515,547

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.41 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 21, 2023 Filed Feb 23, 2023 11:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 228 $4.49 $1,023.72
Disclosure

SEC source: 0001127602-23-006606 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 514,474

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.41 to $4.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 17, 2023 Filed Feb 21, 2023 11:58 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 75 $4.25 $318.75
Disclosure

SEC source: 0001127602-23-006047 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 514,246

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 16, 2023 Filed Feb 21, 2023 11:58 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 62 $4.25 $263.50
Disclosure

SEC source: 0001127602-23-006047 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 514,171

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 15, 2023 Filed Feb 16, 2023 11:46 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 10 $4.25 $42.50
Disclosure

SEC source: 0001127602-23-005440 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 514,109

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 14, 2023 Filed Feb 16, 2023 11:46 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 198 $4.25 $841.50
Disclosure

SEC source: 0001127602-23-005440 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 514,099

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
February 10, 2023 Filed Feb 14, 2023 11:58 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 337 $4.25 $1,432.25
Disclosure

SEC source: 0001127602-23-005031 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 513,901

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.24 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
January 26, 2023 Filed Jan 27, 2023 12:15 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 227 $4.24 $962.48
Disclosure

SEC source: 0001127602-23-002395 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 513,564

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
January 25, 2023 Filed Jan 27, 2023 12:15 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 9 $4.25 $38.25
Disclosure

SEC source: 0001127602-23-002395 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 513,337

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 30, 2022 Filed Jan 3, 2023 12:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 500 $3.50 $1,750.00
Disclosure

SEC source: 0001127602-23-000002 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 513,328

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 30, 2022 Filed Jan 4, 2023 22:50 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 GrantStock Options · Derivative 3,807 $0.00 Strike: $3.51 $0.00
Disclosure

SEC source: 0001127602-23-000649 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 3,807

Underlying: Common Stock · 3,807 shares

Expires 2032-12-30

F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 29, 2022 Filed Jan 3, 2023 12:42 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 1,471 $3.49 $5,133.79
Disclosure

SEC source: 0001127602-23-000002 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 512,828

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.46 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 28, 2022 Filed Dec 29, 2022 12:43 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 1,266 $3.41 $4,317.06
Disclosure

SEC source: 0001127602-22-028331 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 511,357

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.345 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 27, 2022 Filed Dec 29, 2022 12:43 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 604 $3.38 $2,041.52
Disclosure

SEC source: 0001127602-22-028331 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 510,091

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.29 to $3.485 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 23, 2022 Filed Dec 27, 2022 13:32 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 981 $3.45 $3,384.45
Disclosure

SEC source: 0001127602-22-028285 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 509,487

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.35 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 22, 2022 Filed Dec 27, 2022 13:32 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 731 $3.34 $2,441.54
Disclosure

SEC source: 0001127602-22-028285 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 508,506

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.25 to $3.42, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 21, 2022 Filed Dec 22, 2022 13:00 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 399 $3.43 $1,368.57
Disclosure

SEC source: 0001127602-22-028136 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 507,775

F2 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.30 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
December 20, 2022 Filed Dec 22, 2022 13:00 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 4,048 $3.53 $14,289.44
Disclosure

SEC source: 0001127602-22-028136 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 507,376

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.42 to $3.70, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
September 19, 2022 Filed Jan 12, 2026 13:44 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 2,700 $3.69 $9,958.68
Disclosure

SEC source: 0001878313-26-000021 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,424,178

F1 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 22:41 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 OtherCommon Stock 7,200 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-027462 · doc4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 503,328

F3 · kind: In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 9,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 7,200 shares of Common Stock for no additional consideration.

F3 · price: In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 9,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 7,200 shares of Common Stock for no additional consideration.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 22:41 UTC MAIA Biotechnology, Inc. MAIA · Entity 6919 PurchaseCommon Stock 200,000 $5.00 $1,000,000.00
Disclosure

SEC source: 0000899243-22-027462 · doc4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 496,128

F1 · kind: These shares were purchased in the initial public offering (the "IPO") of MAIA Biotechnology, Inc. (the "Issuer"), which closed on August 1, 2022.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.